scorecardresearch
Add as a preferred source on Google
Saturday, November 15, 2025
TopicOxford vaccine

Topic: Oxford vaccine

Delaying 2nd AstraZeneca vaccine shot by upto 45 weeks improves immune response: Oxford study

A preprint of the study by researchers of Oxford University noted that a third dose of the AstraZeneca vaccine will also lead to a substantial increase in immune response.

Covid-19 pandemic: Brussels seeks EU unity over AstraZeneca, push for J&J vaccine in Hong Kong

As the Covid-19 pandemic shows no signs of letting up, ThePrint highlights the most important stories on the crisis from across the globe.

Study of Oxford-AstraZeneca vaccinations in children paused after blood clots emerge in adults

UK’s drug regulator is investigating rare cases of blood clots in adults who were given Oxford-AstraZeneca shot. No safety issues have arisen in children’s trial, Oxford says.

Drug regulator DCGI extends shelf life of Covishield vaccine from 6 to 9 months

In a letter to the Serum Institute, Drugs Controller General of India Somani said the institute is permitted to apply the shelf life of 9 months to unlabeled vials available on hand.

Govt tracking AstraZeneca vaccine ‘blood clot’ issue, but no ‘signal of concern’ yet

NITI Aayog’s Member (Health) Dr V.K. Paul says vaccinations with the Serum Institute of India-made Covishield will continue ‘with full vigour’.

Oxford-AstraZeneca vaccine safe and works extremely well, says UK PM Boris Johnson

Amid reports that doses were causing blood clot-related complications, Johnson said that six months since its discovery, multiple countries like India are producing the vaccine.

3-month gap between doses of Oxford vaccine more effective against Covid, Lancet study finds

According to Oxford University researchers, the first dose of the vaccine offers 76% protection, making it safe for the interval between doses to be extended to 3 months.

Serum Institute, UNICEF sign pact for supply of 1.1 billion doses of AstraZeneca, Novavax

UNICEF will have access to these vaccines for around 100 countries, for approximately USD 3 a dose for the low- and lower middle-income countries.

Covaxin a ‘buffet’ vaccine that can deal with mutations, others ‘a la carte’ — top virologist

India’s vaccination strategy is smartly-designed and will strengthen healthcare workers to handle a second wave, says Dr V. Ravi, former basic sciences dean at NIMHANS.

Malaysia healthcare at ‘breaking point’, UK pharmacies set to offer vaccine & other Covid news

As the Covid-19 pandemic shows no signs of letting up, ThePrint highlights the most important stories on the crisis from across the globe. 

On Camera

Why Tejashwi Yadav failed—Bihar changed, RJD didn’t

RJD, once a prominent representative of Mandal politics, now finds itself in a political era where welfare, good governance, and new aspirations are overshadowing old caste equations.

Wealth nears $99 trillion, still Asia’s rich don’t have succession plans

Much of this wealth is tied to founder-led businesses that employ millions and help anchor regional economies.

Drone manufacturer ideaForge wins orders worth over Rs 100 crore from Army

ideaForge has formed a joint venture to manufacture and market UAVs in the US. Its Q6 UAV is now included in NATO and allied procurement systems.

INDIA has a Congress-sized hole. And the fix begins with a little humility

Without a Congress revival, there can be no challenge to the BJP pan-nationally. Modi’s party is growing, and almost entirely at the cost of the Congress.